Abstract:The major drawbacks of P-glycoprotein (P-gp) inhibitors at the clinical stage make the development of new P-gp inhibitors challenging and desirable. In this study, we reported our structure–activity relationship studies of 4-indolyl quinazoline, which led to the discovery of a highly effective and orally active P-gp inhibitor, YS-370. YS-370 effectively reversed multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 bound directly to P-gp, did not alter expression or subcellular localization of P-gp in SW620/AD300 cells, but increased the intracellular accumulation of paclitaxel. Furthermore, YS-370 stimulated the P-gp ATPase activity and had moderate inhibition against CYP3A4. Significantly, oral administration of YS-370 in combination with paclitaxel achieved much stronger antitumor activity in a xenograft model bearing SW620/Ad300 cells than either drug alone. Taken together, our data demonstrate that YS-370 is a promising P-gp inhibitor capable of overcoming MDR and represents a unique scaffold for the development of new P-gp inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01452.Coordinates of modeled structures in PDB format: YS-370 in complex with ABCB1 (PDB code: 7A6E) (PDB)Cell survival rates under the nontoxic concentration of compounds toward selected cancer cells and NMR, HRMS, and HPLC spectra of compounds 3–45 (PDF)Molecular formula strings (CSV)This article has not yet been cited by other publications.

Design, Synthesis and Biological Evaluation of Seco-Dsp/dck Derivatives Reversing P-glycoprotein-mediated Paclitaxel Resistance in A2780/T Cells

New Seco-DSP Derivatives As Potent Chemosensitizers.

Seco-4-methyl-DCK Derivatives As Potent Chemosensitizers

Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel

Novel pyxinol amide derivatives bearing an aliphatic heterocycle as P-glycoprotein modulators for overcoming multidrug resistance

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety As Orally Bioavailable Reversal Agents Against P-Glycoprotein-Mediated Mutidrug Resistance.

Design, Synthesis and Biological Evaluation of Biaryl Amide Derivatives As Modulators of Multi-Drug Resistance

Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell

Discovery of (quinazolin-6-yl)benzamide derivatives containing a 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Synthesis and Evaluation of Novel Podophyllotoxin Derivatives As Potential Antitumor Agents.

Discovery of novel pyrazolo[1,5-a]pyrimidine derivatives as potent reversal agents against ABCB1-mediated multidrug resistance

Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol and tetrandrine on the reversion of multidrug resistance in K562/A02 cells.

Discovery of the Triazolo[1,5- a ]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance

Synthesis and biological evaluation of thiophenylbenzofuran derivatives as potential P-glycoprotein inhibitors

Discovery of novel third generation P-glycoprotein inhibitors bearing an azo moiety with MDR-reversing effect

Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors

Exploration of 1,2,3-Triazole-pyrimidine Hybrids As Potent Reversal Agents Against ABCB1-mediated Multidrug Resistance

Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance

Discovery of oral chemotherapeutic reversal agents for treating multidrug resistance cancer

Design, Synthesis, and Biological Evaluation of Marine Lissodendrins B Analogues as Modulators of ABCB1-Mediated Multidrug Resistance

Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor